Longevity startup Loyal is working on a drug to extend the lifespan of dogs

From Bay Area Inno. When Loyal CEO Celine Halioua received a letter from the FDA offering approval of the effectiveness of its drug, it felt like the best day of her life.   The company, which is developing therapies to extend the lifespan of dogs, is the first of a handful of similar startups that has made it to the next stage of development: clinical trials. Last November, the FDA approved the Reasonable Expectation of Effectiveness section in Loyal’s application for conditional approval of…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news